Vera Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: VERA · Form: 8-K · Filed: May 17, 2024 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | May 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Vera Therapeutics held a shareholder vote on May 15th. Details filed today.
AI Summary
Vera Therapeutics, Inc. filed an 8-K on May 17, 2024, reporting on matters submitted to a vote of security holders on May 15, 2024. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 8000 Marina Boulevard, Suite 120, Brisbane, California.
Why It Matters
This filing indicates that Vera Therapeutics held a shareholder vote, which is a routine but important corporate governance event that can impact company direction and shareholder rights.
Risk Assessment
Risk Level: low — This is a routine corporate filing regarding a shareholder vote, not indicating any immediate financial or operational risks.
Key Players & Entities
- Vera Therapeutics, Inc. (company) — Registrant
- May 15, 2024 (date) — Date of earliest event reported
- May 17, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 8000 Marina Boulevard, Suite 120, Brisbane, California 94005 (address) — Principal executive offices
FAQ
What specific matters were submitted to a vote of Vera Therapeutics' security holders on May 15, 2024?
The filing states that the report concerns 'Submission of Matters to a Vote of Security Holders' on May 15, 2024, but does not detail the specific proposals voted upon within this 8-K document itself.
When was Vera Therapeutics, Inc. incorporated?
Vera Therapeutics, Inc. was incorporated in Delaware.
What is the address of Vera Therapeutics' principal executive offices?
The principal executive offices of Vera Therapeutics, Inc. are located at 8000 Marina Boulevard, Suite 120, Brisbane, California 94005.
What is Vera Therapeutics' IRS Employer Identification Number?
Vera Therapeutics' IRS Employer Identification Number is 81-2744449.
What is the SIC code for Vera Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Vera Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-05-17 17:15:10
Key Financial Figures
- $0.001 — hich registered Class A common stock, $0.001 par value per share VERA The Nasdaq
Filing Documents
- vera-20240515.htm (8-K) — 58KB
- 0000950170-24-061872.txt ( ) — 174KB
- vera-20240515.xsd (EX-101.SCH) — 26KB
- vera-20240515_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 15, 2024, Vera Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of March 18, 2024, the record date for the Annual Meeting, 54,451,375 shares of Class A common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Proposal 1. Election of Directors The Company's stockholders elected the three persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Andrew Cheng, M.D., Ph.D. 27,436,839 12,964,536 1,020,833 Scott Morrison 31,636,040 8,765,335 1,020,833 Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 41,413,260 1,832 7,116 —
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vera Therapeutics, Inc. Date: May 17, 2024 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer